Filings Radar

SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.

ProQR Therapeutics N.V. (PRQR)

CIK 0001612940 2 material events

Insider activity (SEC Form 4)

Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.

Open-market · last 30 days: 2 buyers bought $988K 0 sellers sold $0
Open-market · last 90 days: 2 buyers bought $988K 0 sellers sold $0
InsiderRoleDateTransactionSharesValue
Filius Bart Director 2026-07-17 Open-market buy 150000 $258K
de Boer Daniel Anton Chief Executive Officer, Director 2026-07-09 Open-market buy 150000 $261K
de Boer Daniel Anton Chief Executive Officer, Director 2026-07-07 Open-market buy 150000 $238K
Filius Bart Director 2026-06-26 Open-market buy 150000 $231K
Most recent 4 reported transactions. Open-market buys (P) and sells (S) are the deliberate ones; grants and option exercises are compensation. Not investment advice.

Operational Other

6-K filed 2026-06-25 confidence 85% EX-99.1

This press release announces positive Phase 1 clinical trial data for AX-0810, ProQR's first Axiomer RNA editing oligonucleotide, demonstrating dose-dependent target engagement on NTCP biomarkers in healthy volunteers with a favorable safety profile. The announcement represents a material clinical milestone validating the company's proprietary RNA editing platform technology and supporting advancement to next-generation candidates and Phase 2 development, which would affect a reasonable investor's assessment of the company's pipeline progress and technology viability.

View raw filing on EDGAR →

Dilutive issuance

6-K filed 2026-06-25 confidence 95% EX-99.1

ProQR announced the pricing of an underwritten registered direct offering of 27.6 million ordinary shares at $1.81 per share for ~$50 million gross proceeds, plus a concurrent private placement of 5.1 million shares to Eli Lilly for ~$9.2 million. This is a material equity issuance that dilutes existing shareholders and raises capital through unregistered (private placement) and registered direct offerings, fitting the dilutive_issuance category. The concurrent private placement to Lilly is explicitly noted as exempt from registration under Section 4(a)(2) of the Securities Act.

View raw filing on EDGAR →